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Abstract
Chemotherapeutic efficacy can be greatly improved by developing nanoparticulate drug delivery 
systems (nano-DDS) with high drug loading capacity and smart stimulus-triggered drug release in 
tumor cells. Herein, we report a novel redox dual-responsive prodrug-nanosystem self-assembled 
by hydrophobic small-molecule conjugates of paclitaxel (PTX) and oleic acid (OA). Thioether 
linked conjugates (PTX-S-OA) and dithioether inserted conjugates (PTX-2S-OA) are designed to 
respond to the redox-heterogeneity in tumor. Dithioether has been reported to show redox dual-
responsiveness, but we find that PTX-S-OA exhibits superior redox sensitivity over PTX-2S-OA, 
achieving more rapid and selective release of free PTX from the prodrug nanoassemblies triggered 
by redox stimuli. PEGylated PTX-S-OA nanoassemblies, with impressively high drug loading 
(57.4%), exhibit potent antitumor activity in a human epidermoid carcinoma xenograft. This novel 
prodrug-nanosystem addresses concerns related to the low drug loading and inefficient drug 
release from hydrophobic prodrugs of PTX, and provides possibilities for the development of 
redox dual-sensitive conjugates or polymers for efficient anticancer drug delivery.
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Nanoparticulate drug delivery systems (nano-DDS) for anticancer drug delivery have 
experienced tremendous development in the past few decades.1–3 However, only a few of 
these formulations could be actually applied in the clinics. Paclitaxel (PTX), a unique 
antimitotic agent, is no exception. Although efforts have been made to improve the 
therapeutic efficacy and reduce the adverse effect of PTX injection (Taxol) by utilizing 
nano-DDS, very few of them can be applied in a clinical setting.4,5 Additionally, the clinical 
outcomes of those commercially available PTX nanoformulations are not as satisfactory as 
expected. Drawbacks of the conventional PTX nano-DDS include low drug loading capacity 
(usually less than 10%), the risk of premature drug leakage in blood circulation, high 
tendency to crystallize during storage, and potential biomaterials-induced toxicity.2 In 
addition to nanotechnology, prodrug formulations have also been extensively studied for 
PTX.5,6 One of the most successful examples is the conjugate of docosahexaenoic acid 
(DHA) and PTX (PTX-DHA, Figure S1A), which has entered into clinical trials.7–10 
However, the outcomes of the recent phase III clinical trials of PTX-DHA conjugate fell 
short of expectations, probably due to the extremely low release rate of PTX in the tumor 
site.10 In another study, it was also reported that almost no free PTX was released from a 
very similar conjugate (PTX-linoleic acid) after 24 h incubation in PBS and plasma.11 
Therefore, it seems clear that a rapid and selective release of free PTX in tumor site from 
prodrugs could be of crucial importance for rational design of hydrophobic PTX-fatty acid 
conjugates.
The redox potential gradient between normal cells and tumor cells has been extensively 
explored for designing stimulus-sensitive nano-DDS.12 Compared to normal cells, tumor 
cells contain a strongly reducing environment due to the overproduction of intracellular 
glutathione (GSH).13 Some tumor cells also simultaneously overproduce reactive oxygen 
species (ROS), leading to increased oxidative stress.14,15 In addition, tumor cells are 
characteristically heterogeneous in terms of redox potential difference.16,17 Overproduced 
GSH and ROS may exist in different tumors or even coexist in different regions in the same 
tumor. Different GSH/ROS levels have also been found at different growth stages of one 
tumor.16,17 However, most stimulus-sensitive nano-DDS were simply designed to respond to 
only one of the redox stimulus (GSH or ROS),18 resulting in partial and limited therapeutic 
efficacy. A dithioether linked amphiphilic conjugate of oligo (ethylene glycol) (OEG) and 7-
ethyl-10-hydroxyl-camptothecin (SN38) had been previously reported to respond to the 
redox heterogeneity in tumor, abbreviated as OEG-2S-SN38 (see the chemical structure in 
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Figure S1B).19 The nanoassemblies of OEG-2S-SN38 conjugates could release SN38 
quickly when triggered by either GSH or ROS.19 Drug release from OEG-2S-SN38 occurred 
via thiolysis by GSH or oxidation of the thioether to hydrophilic sulfoxide or sulfone by 
ROS.19,20 Inspired by these findings, we proposed that a dithioether linker may also 
facilitate the rapid and selective drug release from the hydrophobic conjugates of PTX and 
fatty acids. Furthermore, according to the redox-responsive mechanism of dithioether,19,20 
we hypothesized that single thioether may have better efficacy than dithioether as a redox 
dual-sensitive linkage. We proposed that the single thioether close to the ester bond 
conjugated to SN38 played the key role in controlling the redox-sensitivity, rather than the 
sulfur atom that is further away from the ester bond (Figure S1B). In addition to the long 
distance, dithioether would consume twice as much GSH or ROS as single thioether does.
To test our hypothesis, two novel redox dual-sensitive PTX-fatty acid conjugates (PTX-S-
OA and PTX-2S-OA) were designed and synthesized by conjugating OA to PTX via single 
thioether bond and dithioether bond as linkages, respectively (Figures 1A and S2). An ester 
bond linked conjugate (PTX-OA) was utilized as nonsensitive control. The chemical 
structures of PTX-S-OA and PTX-2S-OA were confirmed by MS, 1H NMR, and IR (Figures 
S3 and S4).
One-step nanoprecipitation method was applied to prepare prodrug nanoparticles (NPs).21 
When these hydrophobic conjugates dissolved in ethanol were injected into deionized water, 
assembly spontaneously occurred. Although the self-assembly of hydrophobic PTX 
conjugates into NPs have been reported elsewhere,21–23 the detailed self-assembly 
mechanism is still unclear now. However, PTX precipitated immediately when it was used to 
perform the same nanoprecipitation process. Therefore, one thing for sure is that the 
hydrophobic moieties conjugated to PTX play key roles in the self-assembly, e.g., the alkyl 
chains of OA, isoprene unit, squalene chain, and vitamin E (Figure S5). Interestingly, what 
they all have in common is that all these moieties have double bond or phenyl group in their 
chemical structures (Figure S5). As a result, the unsaturated alkyl chains or phenyl group 
may facilitate the intermolecular π–π stacking with the planar structures of PTX (Figure 
S6). In addition, the unsaturated alkyl chain of OA would provide flexible steric structures of 
the hydrophobic conjugates (Figure S6). Therefore, the sufficient structural flexibility and 
possible intermolecular π–π stacking would facilitate thermodynamic feasible status with 
the lowest possible energy state during the self-assembly of the PTX conjugates.
To achieve long systemic circulation in blood, tocopheryl polyethylene glycol 2000 
succinate (TPGS2k, 15% w/w) was added to the prodrug in ethanol prior to precipitation. 
Dynamic light scattering (DLS) was utilized to determine the particle size and zeta potential. 
The average diameter of prodrug NPs was around 100 nm (Figure S7), and the zeta potential 
was determined to be −30 to −50 mV (Table S1). Transmission electron microscopy (TEM) 
images also revealed the successful fabrication of prodrug NPs with regularly spherical-
shaped structures (Figure S8). The PEGylated prodrug NPs (PTX-OA/TPGS2k NPs, 
PTX-2S-OA/TPGS2k NPs, and PTX-S-OA/TPGS2k NPs) showed significantly higher drug 
loading efficiency (54.9–66.5% of free PTX, w/w) compared to conventional 
nanoformulations of PTX (usually less than 10%, w/w).4,5 High drug loading efficiency will 
greatly facilitate chemotherapeutic efficiency and reduce excipient-associated toxicities.
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Although the conjugates of PTX and OA could self-assemble into NPs in deionized water 
without any surfactant (Figure S8), non-PEGylated formulations showed poor stability in 
PBS due to the highly hydrophobic surface. As shown in Figure S9, the hydrated sheath of 
non-PEGylated prodrug NPs was destroyed by the salts in PBS and precipitated. To address 
this issue, a small amount of TPGS2k was added to prepare PEGylated prodrug NPs for 
improved stability. As shown in Figure S10A, the PEGylated prodrug NPs showed good 
colloidal stability in PBS (pH 7.4) supplemented with 10% FBS at 37 °C for 48 h. In 
addition, these PEGylated prodrug NPs remained stable after being stored for three months 
at 4 °C (Figure S10B).
We then investigated the in vitro redox dual-responsivity of PTX-S-OA and PTX-2S-OA, 
with the expectation that the redox responsiveness of single thioether linkage would increase 
when compared with dithioether linkage. As shown in Figure 2, there was almost no PTX 
released from PTX-OA/TPGS2k NPs after incubation in PBS (pH 7.4) with H2O2 (a 
prevailing ROS simulatant) or dithiothreitol (DTT, a prevailing GSH simulatant). In 
comparison, both PTX-S-OA/TPGS2k NPs and PTX-2S-OA/TPGS2k NPs exhibited redox-
responsive drug release in the presence of two opposite stimuli, as expected (Figure 2B–E). 
More importantly, PTX-2S-OA/TPGS2k NPs exhibited quite a slower release rate, with 
~46% of the total amount of prodrug hydrolyzed in the presence of 10 mM H2O2 over 12 h 
(Figure 2C,D). In contrast, more than 90% of PTX-S-OA was hydrolyzed within 6 h under 
the same conditions (Figure 2B,D). In addition, PTX-S-OA/TPGS2k NPs released drug at a 
faster rate in the presence of 10 mM DTT than PTX-2S-OA/TPGS2k NPs. More than 50% of 
the total amount of PTX was released from PTX-S-OA/TPGS2k NPs in 48 h (Figure 2E). In 
contrast, only 26% of PTX-2S-OA was hydrolyzed under the same conditions (Figure 2E). 
The in vitro release results confirmed our hypothesis that the thioether bond would provide a 
distinct advantage in redox dual-responsivity over the dithioether bond in terms of redox 
dual-responsivity.
The redox dual-responsive mechanism of PTX-S-OA was illustrated in Figure 3B. For GSH 
triggered drug release, it has been reported that the thiolysis process, initiated by the thiol 
group of GSH, facilitated the drug release from prodrugs.19 Drug release in response to ROS 
may take place in three steps (Figure 3): (i) oxidation of the thioether to hydrophilic 
sulfone;20 (ii) hydrolysis of oleic acid 2-hydroxyethyl ester; (iii) release of active PTX 
molecule. After the thioether was oxidized to a hydrophilic sulfone, the proximal ester bond 
would be more easily hydrolyzed. The oleic acid 2-hydroxyethyl ester was attacked first, due 
to its decreased steric hindrance. Once the long lipophilic OA chain was removed, another 
ester bond conjugated with PTX could be readily hydrolyzed, and the free PTX molecules 
were released.
The question of why OEG-2S-SN38 underwent rapid hydrolysis under redox conditions but 
PTX-2S-OA did not also begs consideration. The most obvious distinction between them is 
that OEG-2S-SN38 is an amphiphilic prodrug and that PTX-2S-OA is a hydrophobic 
conjugate. In addition, PTX is a much larger hydrophobic molecule than SN38. That means 
that the ester bond of OEG-2S-SN38 is much more susceptible to attack by water molecules 
than that of PTX-2S-OA, leading to faster release rate of SN38 from OEG-2S-SN38. The 
hydrophilic properties of OEG-2S-SN38 magnified the redox-responsive capability of 
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dithioether. By comparison, the higher redox dual-responsivity of PTX-S-OA compared with 
PTX-2S-OA may be a result of the following: (i) the single thioether close to the ester bond 
conjugated with PTX is the key point to initiate the GSH/ROS-triggered drug release (Figure 
3A); (ii) dithioether consumes twice as much GSH/ROS as single thioether does; (iii) the 
dithioether linker further extend the hydrophobic chain of prodrug (Figure 3), leading to less 
efficient attack of water molecules; and (iv) the ethylidene between the two thioether bonds 
in PTX-2S-OA increase the hydrophobicity of the surrounding environment around the 
thioether (Figure 3A), which was detrimental to the interaction with GSH and ROS. As a 
result, single thioether showed much higher redox dual-responsivity than dithioether.
We next compared the in vitro cytotoxicity of PTX-S-OA/TPGS2k NPs and PTX-2S-OA/
TPGS2k NPs in three human cancer cell lines, namely, a human epidermoid carcinoma cell 
line (KB-3–1), a human lung carcinoma cell line (H460), and a human ovarian carcinoma 
cell line (OVCAR-8). An MTT assay was used to determine cell viability after 48 or 72 h. 
The IC50 values were calculated and summarized in Table S2. Compared to Taxol, these 
prodrug NPs were less effective in killing cancer cells in vitro due to the delayed release of 
the active PTX molecule (Figures 4 and S11). Among these prodrug NPs, PTX-S-OA/
TPGS2k NPs showed much greater cytotoxicity than PTX-2S-OA/TPGS2k NPs and PTX-
OA/TPGS2k NPs. Additionally, the released PTX by the end of the incubation of KB-3–1 
cells with the prodrug NPs was determined. As shown in Figure S12, much more PTX 
molecules were released from PTX-S-OA/TPGS2k NPs than that from PTX-2S-OA/TPGS2k 
NPs and PTX-OA/TPGS2k NPs at both 48 and 72 h. The in vitro cytotoxicity results were 
consistent with the results of the in vitro release experiment, which further confirmed that 
single thioether had better redox dual-responsivity than dithioether. In addition, the in vitro 
cytotoxicity results indicated that a rapid and selective release of active PTX molecule 
within tumor cells will facilitate the drug-induced apoptosis of tumor cells.
The cellular uptake of prodrug NPs was investigated in KB-3–1 cells. Coumarin-6 (C-6) was 
coassembled with prodrugs to form C-6-labeled prodrug NPs. As shown in Figures 4C,D 
and S13, the cellular uptake of free C-6 and C-6-labeled prodrug NPs was time-dependent, 
and C-6-labeled prodrug NPs displayed significantly higher intracellular fluorescence 
intensity than that of free C-6 at either 0.5 or 2 h.
The pharmacokinetic profiles of Taxol, PEGylated prodrug NPs, and non-PEGylated 
prodrug NPs were studied in Sprague–Dawley (SD) rats. For direct comparison of different 
nanoformulations, the sum of PTX and prodrug molar concentration–time curves were 
summarized in Figure S14, and the respective prodrug and PTX molar concentration–time 
curves were exhibited in Figures S15–S17. The pharmacokinetics parameters were 
calculated and summarized in Table S3. As shown in Figure S14, free PTX was rapidly 
cleared from blood due to its short half-life. In addition, the non-PEGylated formulations 
exhibited an even shorter blood circulation time than that of Taxol due to the poor stability 
and the highly hydrophobic surface of NPs, which could be easily phagocytosed by the 
reticuloendothelial system (RES). By contrast, PEGylated prodrug NPs exhibited 
significantly prolonged retention in blood. In addition to the improved colloidal stability, the 
PEG chains on the outer surface of prodrug NPs played an important role in avoiding 
identification and phagocytosis by RES.24 As displayed in Table S3, the half-life (t1/2) and 
Luo et al. Page 5





















the mean residence time (MRT) of both prodrugs and PTX were significantly extended in 
the groups of PEGylated prodrug NPs when compared with Taxol and non-PEGylated 
formulations, indicating the prolonged blood-circulation by PEGylation.
The ex vivo biodistribution of prodrug NPs was studied in nude mice bearing KB-3–1 tumor. 
As shown in Figure S18, the ex vivo fluorescence images showed that DiR-labeled prodrug 
NPs exhibited significantly increased fluorescence intensity in tumor compared to free DiR. 
Negligible fluorescence signal of free DiR was found in tumors. By contrast, strong 
fluorescence signal was found in liver and tumors treated with DiR-labeled prodrug 
nanoformulations, and the fluorescent signal in tumors increased over time from 4 to 24 h. 
These results were well consistent with the pharmacokinetic studies described above. In 
addition to the long systemic circulation, the EPR effects of prodrug NPs also greatly 
facilitated the intratumoral accumulation of dye.
The favorable stability, drug release, cytotoxicity, and pharmacokinetics of PTX-S-OA/
TPGS2k NPs make it a promising candidate for further clinical evaluation. The in vivo 
antitumor efficacy of prodrug NPs was evaluated in nude mice bearing KB-3–1 xenograft 
tumors. PBS, Taxol, PTX-OA/TPGS2k NPs, PTX-2S-OA/TPGS2k NPs, and PTX-S-OA/
TPGS2k NPs were administrated intravenously every other day for a total of 5 injections at a 
dose equivalent to 8 mg kg−1 of PTX. As shown in Figure 5, PBS and PTX-OA/TPGS2k 
NPs groups showed a rapid increase in tumor volume (~1100–1300 mm3 at day 10). In 
contrast, PTX-2S-OA/TPGS2k NPs and Taxol were able to somewhat suppress tumor 
growth, but the tumor volume reached about 450–700 mm3 at day 10. As expected, mice 
treated with PTX-S-OA/TPGS2k NPs exhibited significantly delayed tumor progression, 
with almost no growth in tumor volume. Notably, DiR-labeled PTX-OA/TPGS2k NPs 
demonstrated comparably high intratumoral accumulation of DiR with DiR-labeled PTX-S-
OA/TPGS2k NPs, but exhibited poor antitumor activity. These results further indicated that 
the low release rate of PTX from hydrophobic ester prodrugs greatly limited their 
chemotherapeutic efficacy, and a rapid and selective release of free PTX in tumor is of 
crucial importance.
PTX-induced apoptosis by each prodrug conjugate was measured using a TUNEL assay. As 
shown in Figure 5D,E, significant tumor cell apoptosis was observed in mice treated with 
Taxol, PTX-2S-OA/TPGS2k NPs, and PTX-S-OA/TPGS2k NPs. PTX-S-OA/TPGS2k NPs 
showed distinct superiority over Taxol and PTX-2S-OA/TPGS2k NPs. In addition, no 
significant change in body weight was observed in any of the mouse populations (Figure 
S19A). The hematological parameters (aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) levels, blood urea nitrogen (BUN), and creatinine) lacked any 
indication of toxicity (Figure S19B). Moreover, no noticeable histological changes were 
observed in H&E-stained tissue sections of heart, liver, spleen, lung, and kidney (Figure 
S20). These results indicated that PTX-S-OA/TPGS2k NPs, despite potent antitumor 
efficacy, showed no significantly nonspecific toxicity to major organs and tissues.
In summary, we successfully developed a novel redox dual-responsive prodrug-nanosystem 
(PTX-S-OA/TPGS2k NPs) assembled by hydrophobic small-molecule prodrugs with 
impressively high drug loading efficiency (over 50% of free PTX, w/w). The ester bond 
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linked prodrug (PTX-OA) showed measurably slower drug release, resulting in poor 
antitumor efficacy. By contrast, redox dual-responsive prodrug-nanosystem presented 
notable advantages. Additionally, the single thioether linked prodrug (PTX-S-OA) was 
distinctly superior to the dithioether-inserted conjugate (PTX-2S-OA) in terms of redox 
dual-sensitive drug release and in vivo antitumor efficacy. To the best of our knowledge, the 
present study is the first in-depth investigation of how tumor-stimuli-responsive linkage 
variations in hydrophobic small-molecule prodrugs correlate with their in vivo antitumor 
activity. This study confirmed our initial hypothesis that the limited clinical outcomes of 
hydrophobic prodrug (PTX-DHA) can be attributed to the extremely slow hydrolysis rate of 
active PTX molecules. This novel prodrug-nanosystem, with impressively high drug loading 
and efficiently selective drug release within tumor site, provides possibilities for the 
development of redox dual-sensitive conjugates or polymers for efficient anticancer drug 
delivery.
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(A) Synthesis of conjugates. (i) PTX, DCC, DMAP, r.t.; (ii) acetic anhydride; (iii) pTsOH, 
reflux; (iv) EDCI, HOBt, DMAP, r.t.; (v) EDCI, HOBt, r.t. (B) Schematic representation of 
the preparation of PEGylated prodrug NPs of PTX-S-OA.
Luo et al. Page 9






















(A) Schematic representation of redox dual-responsive drug release of prodrug NPs in the 
presence of two opposite stimuli within tumor cells. PTX release from (B) PTX-S-OA/
TPGS2k NPs and (C) PTX-2S-OA/TPGS2k NPs in the presence of various concentrations of 
H2O2. PTX release from PTX-S-OA/TPGS2k NPs, PTX-2S-OA/TPGS2k NPs, and PTX-OA/
TPGS2k NPs in the presence of (D) 10 mM H2O2 and (E) 10 mM DTT (n = 3).
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(A) Chemical structure of PTX-2S-OA. (B) Redox-sensitive drug release mechanism of 
PTX-S-OA triggered by GSH/ROS.19,20
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Cell viability treated with various concentrations of Taxol and prodrug NPs after (A) 48 h 
and (B) 72 h treatment. (C) Confocal laser scanning microscopy (CLSM) images of KB-3–1 
cells incubated with free C-6 or C-6-labeled prodrug NPs for 2 h. (D) Cellular uptake in 
KB-3–1 cells after incubation with free C-6 or C-6-labeled prodrug NPs for 0.5 and 2 h by 
flow cytometry. Difference from C-6-Sol group, **P < 0.01, ***P < 0.001.
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In vivo antitumor activity of prodrug NPs against KB-3–1 xenograft tumors (n = 5). (A) 
Tumor growth profiles treated with different formulations. (B) Images of tumors after the 
last treatment. (C) Tumor burden after the last treatment. (D) TUNEL assay quantitative 
results of tumor sections after the last treatment by ImageJ software. (E) TUNEL assay 
images of tumor sections after the last treatment, scale bar represents 500 μm. The data are 
presented as means ± SD, *P < 0.05, **P < 0.01, and *** P < 0.001. Scale bar represents 
500 μm.
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